Trial Profile

A Phase II Clinical Trial of MK-3475 (Pembrolizumab) in Subjects With Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 31 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

19 Sep 2024 This trial has been completed in Spain (Global end date:2023-09-18) according to European Clinical Trials Database record.
29 Sep 2023 Status changed from active, no longer recruiting to completed.
15 Jun 2023 Results of post hoc analysis assessing relative efficacy of favezelimab + pembrolizumab (n=27 from MK-4280-003 study) compared with pembrolizumab alone (n=123 from study KEYNOTE 087) in patients with PD-1 refractory R/R cHL presented at the 28th Congress of the European Haematology Association

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com